Abstract▲ Valsartan, an orally active nonpeptide angiotensin II (AII) receptor antagonist with
selectivity for the AII type I (AT 1) receptor subtype, has recently been approved by the US …

Background. Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

OBJECTIVE: To evaluate the evidence for valsartan in the treatment of heart failure and
determine its need for formulary inclusion. DATA SOURCES: OVID and PubMed databases …

Objective: To evaluate the effect on cardiac hemodynamic parameters of valsartan in
patients with chronic stable congestive heart failure previously untreated with ACE inhibitors …

Abstract Abstract Valsartan (Diovan®) is an oral angiotensin II-receptor antagonist with
specificity for the angiotensin II type 1 receptor subtype. It demonstrates antihypertensive …

Objectives: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was
performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the …

Angiotensin II receptor blockers (ARBs) are the most recent class of anti‐hypertensive drug
to enter clinical use for chronic heart failure (CHF). In the landmark Valsartan Heart Failure …

Heart failure (HF) still has a discouraging prognosis. Therapeutic strategies aim to reduce
mortality as well as slow the progression of the disease, improve symptoms and reduce the …

Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale
randomized, multinational clinical study to assess the efficacy and safety of valsartan, an …